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Abstract: 
Apolipoprotein (Apo), a protein portion of plasma lipoprotein, can attach to and distribute 
blood lipids to different tissues in the body for metabolism and utilization. It is primarily 
synthesized in the liver and, to a lesser extent, in the small intestine. High levels of apolipo-
proteins may affect blood lipid metabolism and use, causing the onset and progression of 
hyperlipidemia and atherosclerosis that might lead to cardiovascular and cerebrovascular 
disease. However, these lipid-protein molecules are also present in extracellular vesicles 
(EVs) samples. The study shows various extracellular vesicle purification methods to detect 
apolipoproteins as well as how the apolipoprotein yield correlates with apolipoproteins and 
cholesterol fractions measured by routine methods in a clinical laboratory. 
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Apo A ja Apo E levimus rakuvälistes vesiikulites kasutades erinevaid 
puhastusmeetodeid 
Lühikokkuvõte: 
Apolipoproteiin (APO), plasma lipoproteiini valguosa, saab kinnitada ja levitada vere 
lipiidid erinevatesse kudedesse kehas ainevahetuse ja ärakasutamise jaoks. See on peamiselt 
sünteesitud maksas ja vähemal määral peensooles. Kõrge apolipoproteiinide tase võib 
mõjutada vere lipiide ainevahetust ja kasutamist, põhjustades hüperlipideemia ja 
ateroskleroosi teket ja edasiarenemist, mis võib viia südame-veresoonkonna ja 
tserebraalhaiguseni. Kuigi need lipiidvalgu molekulid esinevad ka rakuvälistes vesiikulite 
(EVs) proovides. Uuring näitab mitmesuguseid rakuväliseid vesiikulite 
puhastamisemeetodeid apolipoproteiinide tuvastamiseks ja samuti ka kuidas 
apolipoproteiini saagis korreleerub apolipoproteiinide ja kolesterooli fraktsioonidega, mis 
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TERMS, ABBREVIATIONS AND NOTATIONS 
Apo - apolipoprotein 
GAM - goat anti-mouse 
GAR - goat anti-mouse 
SDS -PAGE - sodium dodecyl sulphate–polyacrylamide gel electrophoresis 
EV – extracellular vesicle 
HDL – high density lipoprotein 
LDL - low density lipoprotein 
IDL - intermediate density lipoprotein 
PBS - phosphate-buffered saline 
PEG - polyethylene glycol 
UC – ultracentrifugation  
min - minutes 
LPL - lipoprotein lipase  
HTGL - hepatic triglyceride lipase 






Extracellular vesicles (EVs) are categorized based on their biogenesis and size. EVs can be 
broken down into exosomes, microvesicles, and apoptotic bodies. All biological fluids, in-
cluding blood, urine, amniotic fluid, saliva, and cerebrospinal fluid, contain EVs (Williams 
et al., 2018).  They are unique markers of pathological processes and cellular activation. 
They also spark considerable interest in the management of cardiovascular diseases and can-
cer (Oggero, Austin-Williams, and Norling, 2019). 
Lipoproteins are lipid-protein particles that transport hydrophobic substances in plasma's 
hydrophilic environment. Their hydrated densities are used to classify them. Lipoprotein 
size, structure, and apolipoprotein content can all change as a result of the action of enzymes, 
including lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL). 
The aims of the thesis are to isolate extracellular vesicles in blood samples using three puri-
fication methods and then detect the presence of apolipoproteins in the purified EVs. We 
also compare our findings with apolipoprotein A, B100 and different cholesterol fractions 
measured in a clinical laboratory. 
The first part of the study gives the literature overview of extracellular vesicles, their various 
sizes, purification methods, analyzing methods that could be utilized; as well as lipoproteins, 
apolipoproteins and atherosclerosis. The experimental part of the study is based on the meth-
ods used to detect apolipoproteins after purification of EVs from selected blood samples. 
This study was performed in the prof. Reet Kurg laboratory in the Institute of Technology, 






1 LITERATURE REVIEW 
1.1 Extracellular vesicles (EVs) 
Extracellular vesicles (EVs) are cell-derived nanovesicles generated from discrete subcellu-
lar compartments and delivered into extracellular space. EVs have a lipid bilayer enclosing 
both soluble cytosolic material and nuclear components, which have an essential role in in-
tercellular communication and are involved in the transport of biological signals for regulat-
ing diverse cellular functions (Williams et al., 2018).  EVs exist in all biological fluids, in-
cluding blood, urine, amniotic fluid, saliva, and cerebrospinal fluid. Their diversified com-
position and biological content represent specific signatures of pathological processes and 
cellular activation. EVs have raised significant interest in cardiovascular diseases and cancer 
management as diagnostic and prognostic biomarkers (Oggero, Austin-Williams and 
Norling, 2019). Various methods for their isolation, detection, and characterization are being 
developed. 
 
1.1.1 Types of EVs 
ll cells (prokaryotes and eukaryotes) release different types of extracellular vesicles (EVs) 
as part of their normal physiological processes. EVs can be broadly grouped into two cate-
gories, exosomes and ectosomes. Exosomes are a type of EVs that include constituents of 
DNA, RNA, and proteins of the cells that secrete them. They are released during multi-
vesicular endosomal fusion with the plasma membrane. Their size is about 40–120 nm in 
diameter. Exosomes transfer molecules from one place to another by membrane vesicle traf-
ficking, thereby exerting influence on the immune system, such as B cells and dendritic cells, 
and may have a functional effect in mediating adaptive immune responses to microbes and 
tumors. Exosomes can be released into urine by the kidneys and can be used as a diagnostic 
tool or as a treatment response marker in prostate cancer (Pisitkun, Shen and Knepper, 2004). 
Exosomes which are released from tumors into the blood may have diagnostic prospects. 
Exosomes are stable in bodily fluids strengthening their usefulness as reservoirs for disease 
biomarkers (Williams et al., 2018). 
Ectosomes, also known as microvesicles are budded from the surface of the plasma mem-
brane. They include microvesicles (100–1000 nm in diameter), and apoptotic bodies (1–5 
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μm in diameter) produced by cell apoptosis (Sunkara, Woo and Cho, 2016). EVs are classi-
fied according to their biogenesis and size. Specific markers and analytic methods are cur-
rently being developed to distinguish the origins of the vesicles upon release into the extra-
cellular matrix since it is quite difficult to differentiate between smaller size vesicles when 
they are isolated together (Sunkara, Woo and Cho, 2016). 
At the point of their discovery, EVs were thought to be involved in cellular excretion of by-
products. As such less attention was given to them until their participation in the immune 
response was revealed. In 2007, it was discovered that they intercede communication be-
tween cells due to the presence of functional RNAs. After that, research experiments on EVs 
has shot up exponentially concentrating on the growth of new methods for the isolation as 
well as analysis of their physiological functions and composition (Sunkara, Woo and Cho, 
2016). 
EV functions are dependent on their composition as well as their origin. Because they carry 
diverse membrane and cytosolic proteins, DNA, mRNA and miRNA, EVs are considered 
prospective biomarkers and are known to be involved in both disease progression and normal 
physiological processes in a pleiotropic manner, including the immune response, cell signal-
ing, antigen presentation, intercellular communication etc. (Sunkara, Woo and Cho, 2016) 
Patients with elevated EVs might have several health conditions, including atherosclerosis 
(Chironi et al., 2006) 
  
1.1.2 Purification Methods 
EVs as potential biomarkers are becoming a growing interest, and various purification tech-
niques have been recently developed (Liga et al., 2015). Additionally, numerous research 
groups compared the efficiency of available purification techniques (Tauro et al., 2012), 
(Caradec et al., 2014), (Lane et al., 2015). Three main classes of isolation techniques can be 







This technique includes ultracentrifugation and regular centrifugation with precipitation re-
agents.   
Ultracentrifugation (UC) 
Low-density particles are separated by applying differential centrifugation by varying g 
forces. For decades, ultracentrifugation greater than 100,000 g has been used to isolate eu-
karyotic viruses, and bacteriophages due to their relatively low densities (McNamara and 
Dittmer, 2020). Ultracentrifugation has become a frequently utilized technique for EV iso-
lation. The fact that ultracentrifugation is generally used in biochemistry and routine molec-
ular biology, makes it a fast and reliable technique for EV isolation. Cells and debris are 
removed at a low g force, although with a high g force of approx. 200,000 g sediments of 
EVs (1.13–1.19 g mL−1) are obtained (Figure 1) (Sunkara, Woo and Cho, 2016). Even so, 
it takes approx. 5 h for isolating the exosomal pellet. Additionally, it requires special equip-
ment, an ultracentrifuge, which might be unavailable in standard laboratory settings. Other 










In recent years several commercial kits which include precipitation reagents have been made 
available for EV isolation. The reagents decrease the solubility by lowering the hydration of 
EVs and lead to precipitation. Polyethylene glycol (PEG) has been utilized for many years 
as a crowding reagent to precipitate complex protein and macromolecule structures out of 
solutions. EVs precipitate at lower speed centrifugation (McNamara and Dittmer, 2020). 
PEG is the principal active element in many exosome precipitation reagents that are available 
commercially. Since viruses and smaller EVs such as microvesicles and exosomes have rel-
atively similar biophysical properties, PEG precipitation has become a generally adopted 
method for EV isolation from fluids such as tissue culture supernatant and plasma. The use 
of PEG in a plasma solution or tissue culture supernatant can be viewed as a molecular fish-
ing net that grabs larger molecules (depending on the molecular weight of the PEG) into a 
dense bundle at the same time allowing smaller molecules to be left in the solution. This 
provides for low-speed centrifugation (< 2000 g) to pellet the virus and or EV aggregates 
(Peterson et al., 2015; Hurwitz et al., 2016; Rider, Hurwitz and Meckes, 2016). 
Precipitation using PEG can be done at lower speeds using desktop centrifuges and can hold 
larger volumes (100ml – 1 L) than ultracentrifuge units. From a cost-of-production view-
point, precipitation with crowding reagents has a great advantage compared to other meth-
ods. Moreover, the principal underlying condition is that the use of crowding reagents with 




EVs can be separated from cells and large debris by using nano-sized membrane filters. 
Filtration is an effective procedure for the removal of large debris, including large vesicles 
of above 200 nm in diameter, subcellular fractions, plasma proteins, protein–nucleic acid 
aggregates, or protein aggregates (Sunkara, Woo and Cho, 2016). Membranes pores of sizes 
of 0.2, 0.22, and 0.45 μm and materials such as polyvinylidene fluoride and track etched 
polycarbonate are widely used to remove large debris. The purity of EVs is enhanced by a 
combination of filtration and ultracentrifugation. Muller et al. reported that the combined 
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method is preferable to using an ultracentrifugation-based technique, differential centrifuga-
tion, or sucrose density gradient alone (Muller et al., 2014). 
Furthermore, apart from membrane filtration, several approaches have been proposed for 
size-based separation of EVs. These techniques include acoustic waves and micro pillar-
based methods. Santana et al. used geometry to isolate vesicles by using the principles of 
deterministic lateral displacement (DLD). Lee et al. used sound waves to purify EVs in a 
contact-free manner. Wang et al. used ciliated micro pillars for multi-scale filtration by re-




Affinity purification of antibody or specific protein-based capture systems such as streptav-
idin, is a way to biochemically purify a discrete population from a heterogeneous mixture. 
The method can be used to separate viruses and EVs given the differences in membrane of 
capsid composition (McNamara and Dittmer, 2019). The common exosomal markers are 
tetraspanins including CD9, CD63, and CD81. These markers are specific to exosomes, and 
the methods aid in the specific isolation of exosomes depending on the capture antibodies 
used. 
To purify EVs and study their relationship with cancer, new isolation techniques utilizing 
microfluidics including paper-based microfluidic devices, immunomagnetic beads, photo-
sensitizer beads etc. are being developed, based on immunoaffinity capture with antibodies 
specific to EVs (McNamara and Dittmer, 2020). Most of these capture beads make use of 
the tetraspanin proteins present on the surface of EVs. Tetraspanins are incorporated onto 
the EV membrane during trafficking through the endosomal recycling pathway. The tetra-
spanin-coated EVs (exosomes) are biologically active post-capture or elution from the beads 
and are competent for uptake by recipient cells (Chugh et al., 2013). Affinity purification 
remains the best standard for isolating a homogenous entity from a heterogeneous input, 




1.1.3 Analytical methods 
Size characterization 
Morphological information and size can be obtained from high-resolution imaging with elec-
tron microscopy using transmission electron microscopy (TEM) or scanning electron mi-
croscopy (SEM). Electron microscopy is an effective tool to determine the morphology, size, 
and existence of surface markers; however, this technique cannot measure the concentration 
of EVs. Nanoparticle tracking analysis (NTA), is another technique that uses particle track-
ing to measure the concentration of EVs and size distribution. 
Surface markers and protein analysis can be done utilizing methods like ELISA, western 
blotting, Bradford’s assay, and flow cytometry. However, these purification techniques re-
quire standardized and optimized protocols. Enzyme-linked immunosorbent assay (ELISA) 
technique provides information about the presence of surface markers. Western blotting 
(WB) is an effective method to visualize the presence of exosomal proteins where isolated 
EVs are lysed, and proteins within EVs are analyzed. Bradford’s assay technique can deter-
mine the total protein content of purified EVs. However, these techniques cannot be applied 
to unpurified samples containing protein contaminants (Sunkara, Woo and Cho, 2016). 
Other analytical methods might include molecular analysis such as fluorescence imaging; 
this method employs a lipophilic dye to capture antibodies in the EVs' lipid bilayer. The 
lipophilic dyes used consist of green fluorescent protein (GFP) or red fluorescent protein 
(RFP) labelled exosomal marker CD63 (Sunkara, Woo and Cho, 2016). Bioanalyzers, quan-
titative reverse transcription polymerase chain reaction (qRT PCR), miRNA arrays, and 
mass spectrometry are generally used for profiling exosomal cargo. Furthermore, reports 
have been made that EVs contain proteins and diverse RNA cargo that include short se-
quences of about 20 – 200 nucleotides. (Sunkara, Woo and Cho, 2016). 
1.2 Apolipoprotein (Apo) 
In order to understand what apolipoproteins are, we must briefly describe what lipoproteins 
are and their relation to apolipoprotein. Lipoproteins are lipid-protein particles that carry 
hydrophobic substances in the hydrophilic environment of plasma (Dominiczak and Caslake, 
2011). They are classified according to their hydrated densities; very-low-density lipopro-
teins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and 
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high-density lipoproteins (HDL). Lipoproteins differ in size, lipid composition, and apolipo-
protein content. These characteristics change due to the action of enzymes such as lipopro-
tein lipase (LPL), hepatic triglyceride lipase (HTGL), lecithin-cholesterol acyltransferase 
(LCAT), and cholesteryl ester transfer protein (CETP) (Dominiczak and Caslake, 2011). 
Apolipoproteins (apo) describe amphipathic molecules with both hydrophilic and hydropho-
bic properties and are therefore able to interact with both lipoprotein lipids and aqueous 
plasma. Together with phospholipids and cholesterol, apolipoproteins form lipoprotein par-
ticles into which several different lipids can be packed. Apolipoproteins also control cellular 
uptake of lipoproteins by binding to membrane-specific lipoprotein recep-
tors.                                            
1.2.1 Types of apolipoprotein 
Apolipoprotein A1 (ApoA1) is a protein composed of 243 amino acids.  The apo A gene is 
located on chromosome 11 and synthesized in the liver and intestine. ApoA1 constitutes 
70% of HDL apolipoproteins, it activates LCAT, and is also an anti-inflammatory molecule 
and an antioxidant. 
Apolipoprotein AII (ApoAII) is mainly expressed in the liver and accounts for approxi-
mately 20% of HDL protein. It consists of 77 amino acids and has a molecular mass of 
17,400 Da. ApoAII concentration is determined by its rate of production and is known to 
inhibit LPL activity, and as a co-factor for CETP and LCAT (Dominiczak and Caslake, 
2011). 
Apolipoprotein AIV (ApoAIV) is synthesized in the intestines and incorporated into nascent 
chylomicrons. It is also in HDL and relatively hydrophilic. It may be displaced from lipo-
proteins and circulates predominantly as a lipid-free protein. It participates in intestinal lipid 
absorption and affects various aspects of lipoprotein response to diet. It also modulates the 
activity of LPL and activates LCAT (Dominiczak and Caslake, 2011). 
ApoAV is synthesized in the liver, controls hepatic VLDL synthesis and secretion. The gene 
coding for apoAV has been strongly related to TG concentration. ApoAV deficiency leads 
to type V dyslipidemia and reduced post-heparin LPL activity. Its overexpression leads to a 
reduction in TG concentration. 
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Apolipoprotein B100 (ApoB100) consists of 4536 amino acids with a molecular weight of 
550,000 Da. It contains a globular amino-terminal domain, which reacts with microsomal 
TG transfer proteins. ApoB gene is found at the short arm of chromosome 2. Copenhagen 
City Heart Study identified 123 genetic variants in the apoB gene. ApoB100 is synthesized 
in the liver and degraded within the liver cells when in excess. ApoB is the core apolipopro-
tein of LDL and chylomicrons (Apolipoproteins. Apo A1, B, C2. Apolipoproteins infor-
mation, 2015). Moreover, it is present in VLDL and LDL particles. 
Apolipoprotein B48 (ApoB48) constitutes 2152 amino acids with a molecular mass of 
264,000 Da. It is the shortened form of apoB100, and it is produced from the same gene as 
apo B100. ApoB48 is synthesized in the intestines in humans and secreted by chylomicrons. 
It is the most appropriate marker for cardiovascular investigation of postprandial chylomi-
cron metabolism. Patsch et al. demonstrated that atherosclerosis could be predicted by post-
prandial lipemia. The plasma concentration of apoB48 corresponded with postprandial lipe-
mia, making apoB48 a biomarker for atherosclerosis (Dominiczak and Caslake, 2011). 
Apolipoproteins C is synthesized mostly in the liver and the intestine. It contributes to the 
assembly of VLDL and chylomicrons. ApoCI is present in TG-rich lipoproteins. ApoCII 
activates LPL and therefore contributes to VLDL lipolysis. ApoCI and apoCIII inhibit LPL 
and HTGL. ApoAV may counteract the effects of apoCIII (Dominiczak and Caslake, 2011). 
Overexpression of apoCIII in humans can lead to atherosclerosis. (Khetarpal et al., 2017) 
Apolipoprotein E (ApoE) is a single-chain glycoprotein that consists of 299 amino acids. Its 
molecular weight is 34,200 Da. It is present in mature VLDL, VLDL remnants, chylomicron 
remnants, LDL, and HDL. It is associated with a high affinity to the LDL-receptor and the 
LDL-receptor protein (LRP). ApoE facilitates the clearance of chylomicron and VLDL rem-
nants. Plasma apoE constitutes approximately 60% of HDL, which exchanges it with other 
lipoproteins. ApoE controls cholesterol outflow from cells together with apoAI. It has anti-
oxidant properties and plays a role in the regulation of inflammatory response (Dominiczak 
and Caslake, 2011). ApoE occurs in three isoforms: E2, E3, and E4. The differences between 
the isoforms are a result of amino acid positions 112 and 158. ApoE initiates HTGL, LPL, 
and LCAT. The affinity of apoE3 and apoE4 to the LDL receptor is similar, while apoE2 
has a lower affinity. Overexpression of apoE leads to hypertriglyceridemia through stimula-
tion of VLDL production (Dominiczak and Caslake, 2011). Apolipoprotein E (apoE) is a 
polymorphic multifunctional protein in humans. It is coded by three alleles (e2, e3, e4) of a 
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modulator gene. ApoE polymorphism regulates susceptibility to many diseases, including 
atherosclerotic arterial disorders and neurodegenerative disorders (Davignon, 2005). The e4 
allele is related to higher LDL-C, and it initiates atherogenesis whereas, allele e2 has the 
opposite effect and is associated with lower LDL-C. However, allele e2 may be in correlation 
with increased plasma triglycerides (Davignon, 2005). Allele and gender-dependent effects 
on oxidative and reverse cholesterol transport make apoE a prospective biomarker in lipo-
protein metabolism and atherogenic diseases. 
1.2.2 Atherosclerosis and apolipoproteins 
The term “atherosclerosis” is defined as the narrowing of the arteries due to fatty deposit 
(plaque) build-up that can reduce blood supply to the heart and other vital organs such as the 
brain and intestines. Plaques mainly consist of low-density lipoproteins cholesterol (LDL- 
C), fibrous tissue, and sometimes calcium deposits. As plaque builds up, it might tear away 
from the blood vessel and form a thrombus that blocks further vessels. Due to the lessening 
of blood vessel open areas with plaque build-up, blood clots may also develop. Both thrombi, 
as well as formed clots, can block downstream arteries, thereby starving vital organs of ox-
ygen and blood. As a result, the organs can be severely damaged or die. Atherosclerosis may 
lead to several life-threatening cardiovascular diseases. These include ischemic heart dis-




2 THE AIMS OF THE THESIS 
It has been shown that extracellular vesicles (EVs) are cell-derived nanovesicles found in 
almost all forms of bodily fluids, with emerging techniques for isolating, detecting, and char-
acterizing being developed in response to the growing clinical interest in their function 
(Sunkara, Woo and Cho, 2016).  
We aimed to:  
● Use different purification methods for extracellular vesicle isolation. 
● Analyze the number of extracellular vesicles present in the purified samples. 
● Detect the prevalence of Apo A and Apo E in differently purified EVs 
● Compare our results with data (apoA, apoB, HDL-, LDL, and total cholesterol) we 




3 EXPERIMENTAL PART  
3.1 MATERIALS AND METHODS 
3.1.1 Blood serum and conditions 
Blood was collected 08.10.2020 from healthy volunteers in the Institute of Technology,  Uni-
versity of Tartu as a part of the Sars-CoV2 antibody study. 4 ml of blood was collected into 
BD Vacuette SSTII Advanced serum separator tubes. After collection, blood was allowed 
set for a minimum of 30 min and then centrifuged at 2000 g for 10 minutes. After centrifug-
ing, 1.5 ml of serum was collected, labeled adequately with a TYTI code, and stored at -20° 
C until further analysis. Table 1. shows the blood samples obtained from the volunteers. 
For clinical cholesterol analysis, 500 µl of serum was sent to Tartu University Central labor-
atory (for LDL-, HDL-, and total cholesterol) and North Estonian Hospital Central labora-
tory (for apo A and apoB100) measurements on Roche Cobas analyzer. 
 
Table 1. Blood samples were obtained from healthy volunteers. Three male and three female 
adult samples were collected for the experiment. 
TYTI/Samples  Sex Age 
8 male 31 
10 female 56 
14 female 25 
38 male 59 
78 female 30 
105 male 54 
3.1.2 Sample Preparation 
All six (6) blood samples obtained from healthy volunteers in Tartu University Technology 
Institute were prepared in three different ways.  
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The first purification method used was ultracentrifugation through PBS(UC/PBS). 200µl of 
serum was put into new 1.5ml Eppendorf® tubes, and 800 µl of PBS was added to the con-
taining sample in the tubes. Next, the solution was centrifuged (1200 x g for 30 min). 1ml 
supernatant was collected and cell pellets discarded. (The supernatant could be stored at -20 
℃ before it can be used later). The process was continued by the addition of 3 ml of PBS 
into ultracentrifugation tubes. The supernatant was added and mixed thoroughly. The ultra-
centrifuge tubes are weighed to make sure they contain the same amount of mixture with a 
difference of +/- 0.02 g. The tubes were then placed in the Beckman Coultier SW55Ti rotor 
and ultracentrifuged for 4 hours at 32,000 rpm (120,000 g). The supernatant was discarded 
and allowed to dry upside down for 5 - 10 min. 200 µl of PBS was added to the tubes and 
allowed to sit for 10 min. After that, cells were resuspended 10 – 20 times to collect all EVs. 
200 µl of resuspended samples are then collected into 1.5 ml Eppendorf® tubes and labeled 
with sample code (UC/PBS) and sample number. 
The second preparation method was precipitation with PEG. Up to a 100 µl of each sample 
was centrifuged at 10,000 g for 10 min at 4°C (Pico 21, Thermo Scientific) to remove un-
soluble material.  Then 20 µl of 50% PEG MW 6000 (final concentration 10%) and 1.5 µl 
of 5M NaCl was added per 100 µl of sample and percipitated overnight at 4°C. EVs were 
centrifuged at 10,000 g for 10 min. and the pellet was resuspended in 200 µl of PBS. 100 µl 
of the sample (diluted in 4 ml of PBS) was ultracentrifuged at 120,000 g for 4 hours with 
Beckman-Coultier SW55Ti rotor. Pellet was resuspended in 200 µl of Dulbecco’s PBS 
(DPBS) (Sigma-Aldrich) and labeled with sample code (PEG/UC) and sample number.  
The third sample preparation method was size exclusion chromatography (SEC). In this 
method, the bottom and top of PURE-EVs Size Exclusion Chromatography columns (Hansa-
BioMed Life Sciences Ltd, Estonia) were opened, and 1 ml of  PBS was pipetted into it. 
With a new SEC column, it was first needed to add 10 ml of  PBS and let it run through to 
wash out the preserving solution, after which 100 µl of serum sample was added into the 
column. 1 ml of PBS is constantly added to the mixture to avoid the top layer from drying 
out. The first 500 ul of the run-through was collected at the bottom of the column into a 
separate 1.5 ml Eppendorf tube and labeled. Thereafter, 100 µl fractions (about three drops) 
were collected for 1000 µl / 10 fractions, and the collected samples were named and marked 
accordingly. Another 500 µl of the run-through is collected into the Eppendorf® tube and 
labeled as a second run-through with sample code. After the run-through was collected, an-
other 10 ml of  PBS was added to wash the column, and the run-through liquid was discarded. 
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Once the column was washed, 500 ml of 1 x PBS was added, and the bottom and top stoppers 
were secured in place. All the collected fractions were labeled with sample code and frac-
tions number (SEC fr), as well as the sample number. 
3.1.3 Gel Electrophoresis and Semi-dry protein transfer 
After samples were prepared, they needed to be run on 10% SDS - PAGE gels and trans-
ferred to Immobilon®-P PVDF membranes (Carl Roth, Germany). To begin the process, 
10% SDS-PAGE gels were prepared with 10% separating gel and 5% stacking gel. Samples 
were prepared for UC/PBS and PEG/UC by mixing 20 µl of 2x Laemlli + DTT with 20 µl 
of  samples. They were kept on 100 °C heat for 10 min, vortexed and centrifuged for 2 min. 
5 µl of PageRuler™ Prestained Protein Ladder, 10 to 180 kDa (Thermo Fischer Scientific, 
USA) was loaded on the first lane of the gel followed by 10 µl of the prepared UC/PBS 
samples to the next lanes. Gel electrophoresis was run between 100 – 150 volts. These pro-
cesses were also repeated for PEG/UC samples. Once the electrophoresis was done, the 
stacking gel was cut – off, and the size of the separating gel was measured. The gel was 
placed in a semi-dry transfer buffer. Six (6) Whatman® Blotting Papers (Merck, Germany) 
and Immobilon®-P PVDF membrane were then cut to identical size to the gel. Three (3) 
Whatman® Blotting Papers were soaked in semi-dry buffer solution, the Immobilon®-P 
PVDF membrane was pre-soaked in methanol for 1 min and then later placed in semi-dry 
buffer solution. The gel was stacked onto the PVDF membrane and then sandwiched to-
gether with the Whatman® Blotting Papers. The assembled sandwich was transferred to the 
semi-dry protein transfer machine and run at 15 volts for 30 min. 
 
Table 2. Ultracentrifugation samples prepared for gel electrophoresis 
Samples (UC/PBS, PEG/UC) Loading volume 
PageRuler™ Prestained Protein Ladder 5 µl 
TYTI 8 10 µl 
TYTI 10 10 µl 
TYTI 14 10 µl 
TYTI 38 10 µl 
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TYTI 78 10 µl 
TYTI 10 10 µl 
3.1.4 Western Blot 
After transfer of proteins to the membranes was completed, the membranes were blocked 
for 1 hour at room temperature of 25 °C in 2% non -fat dried (NFDM) milk prepared in WB–
washing buffer. Membranes were subsequently transferred and incubated in primary anti-
body solution (2% NFDM in WB- Washing buffer) against the target protein (apo A1, apo 
E) for 1 hour at room temperature. The blot was rinsed 3x for 10 min with WB- Washing 
buffer and incubated in HRP- conjugated secondary antibody solution (2% NFDM in WB- 
Washing buffer) for 45 min with the corresponding primary antibody. Table 3. shows the 
overview of the sample purification methods and the concentration of antibodies used in the 
process. The blot rinsing was repeated (3x for 10 min). The imaging of proteins of interest 
was performed by applying a chemiluminescence substrate to the blot according to manu-
facturer recommendation, and signals were captured using an X-ray film. 
Table 3.  Purification methods and corresponding antibodies concentrations used in Western 
blotting 




Apo A1, 26 kDa 1:1000 Goat anti-mouse (GAM) 1:10000  
  
Apo E, 36 kDa 1:2000 Goat anti-rabbit (GAR) 1:10000  
Western Blots PEG/UC 
samples 
Apo A1, 26 kDa 1:1000 Goat anti-mouse (GAM) 1:10000  
  





Apo A1, 26 kDa 1:1000 Goat anti-mouse (GAM) 1:10000  
  
Apo E, 36 kDa 1:2000 Goat anti-rabbit (GAR) 1:10000  
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3.2 RESULTS  
3.2.1 Clinical laboratory analysis 
Clinical data show that LDL – cholesterol and total cholesterol of samples 10 and 105 were 
the above normal value (marked in red). At the same time, HDL was relatively higher in all 
samples except sample 38. 







































8 3.8 1.16 2.11 2.64 46 1.3 male 31 
10 6.5 1.44 3.86 5.06 64 2.28 female 56 
105 6.6 1.89 3.74 4.71 62 1.05 male 54 
38 2.5 0.85 1.17 1.65 62 1.62 male 59 
14 3.7 1.57 1.47 2.13 63 1.26 female 25 
78 4.3 1.79 2.07 2.51 54 1.64 female 30 
 
3.2.2 Purification and analysis of extracellular vesicles  
After SEC fractions were done, one sample, TYTI 38, was used to determine the number of 
proteins purified in all SEC collected fractions. For this, sample fractions of TYTI 38 were 
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selected and run on 10% SDS-PAGE gel with 5µl PageRuler™ Prestained Protein Ladder 
marker on the first lane followed by the fractions 3 to 10. The gel was put in Page Blue 
protein stain overnight after electrophoresis was completed. The gel was rinsed in distilled 
water for about 5 to 6 hours, and the gel was scanned. From the picture in (Figure 2), we can 
choose which SEC purified fractions should be used for Western blotting and also determine 
the fractions which contain EVs. The same SEC fraction samples of TYTI 38 were sent to 
Particle metrix laboratory for Zetaview Nanoparticle tracking analysis to determine the con-
centration of EVs in the samples. The results obtained can be seen in the Figure 3 graph. 
Page Blue staining image representation is compared to the graph in Figure 2, where some 
parallels between the images can be found (Figure 3). 
 
Figure 2. Page Blue protein staining of SEC fractions of sample TYTI 38 showing the 
various bands of proteins sizes from fraction 3 to 10. As shown in the diagram above, frac-
tion 4 contains the most significant number of EVs.  
 
 
Figure 3. Zetaview Nanoparticle tracking analysis graph obtained from using SEC frac-
tion of TYTI 38. The diagram illustrates the concentration of detected particles per milliliter 
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(mL) in corresponding fractions and shows the number of EVs in the fraction samples. For 
example, fraction 4 has the highest peak (27 x 1010 Particle/mL), according to the above 
graph in figure 2.   
 
3.2.3 Western Blot results 
Six TYTI samples were used for Western blot analysis. The Western blot analysis was done 
using UC/PBS and PEG/UC (Figure 4, Figure 5). Samples where secondary antibodies, 
GAM and GAR, were used against primary antibodies apo A1 and apo E respectively to 
confirm apolipoproteins in the samples. Apo A1 and apo E were detected at 26 kDa and 46 
kDa, respectively, in UC/PBS samples. PEG/UC samples with Western blotting showed apo 
A1 and apo E were 26 kDa and 36 kDa, respectively. The final analysis was done using SEC 
fractions (Figure 6). The primary antibody used was apo E with secondary antibody GAR. 
Apo E was detected at 36 kDa. The result obtained from Western blotting is a confirmation 




Figure 4. Analysis of  Apo A1 and Apo E of  UC/PBS purification method.  A: Detection 
of Apo E in UC/PBS samples. The expected protein size is 36 kDa. B: Detection of Apo A1 
in UC/PBS samples. The expected protein size is 26 kDa. The greater the intensity of the 
bands, the greater the number of target proteins present in the samples. UC/PBS demon-




Figure 5. Analysis of confirmation of protein sizes of Apo A1 and Apo E using PEG/UC 
method for apolipoprotein detection. A: Detection of Apo E in PEG/UC samples with sec-
ondary antibody, GAR. The expected proteins size is 36 kDa. B: Detection of Apo A1 in 
PEG/UC samples with secondary antibody, GAM. The expected protein size is 26 kDa. Fur-
thermore, strong bands indicate the number of target proteins in the samples. PEG/UC have 
also shown an outstanding method for detecting apolipoproteins. 
 
 
Figure 6.  Analysis of the Apo E protein after SEC purification method. The intensity of 






3.3 DISCUSSION AND CONCLUSION 
Metabolism of lipoproteins is based on apolipoproteins. These multifunctional proteins act 
as templates for the assembly of particles of lipoprotein, preserve their structures, and guide 
their metabolism by binding them to membrane receptors (Dominiczak and Caslake, 2011). 
Lipoproteins can co-purify with extracellular vesicles. To detect apolipoproteins in extracel-
lular vesicles from blood samples, as potential biomarkers or immunological studies for 
prognostic and prediction responses to therapies, they must first be isolated without losses 
as biologically purified active vesicles. There are currently several commercially established 
approaches for the enhancement and isolation of EVs (Muller et al., 2014).  
The main question here is whether we could detect apolipoproteins in samples of extracel-
lular vesicles. To determine the presence of apolipoprotein in EVs, first three isolation meth-
ods were used to purify the EVs, which included ultracentrifugation through PBS, ultracen-
trifugation through PEG, and by size exclusion chromatography. However, according to the 
Western blotting results obtained from the above experiments in Figure 4, Figure 5, and 
Figure 6, it can be shown that apolipoproteins can be detected on all differently purified EVs. 
Similar research conducted by (Hirowatari et al., 2010) also used sequential ultracentrifuga-
tion and chromatography methods for purifying blood serum and then analysed results with 
Western blotting to confirm the presence of apolipoproteins in the blood samples. They used 
two goat polyclonal antibodies against apo A1 and apo B and one goat polyclonal antibody 
against apo E. The results they obtained from the bands of apo A1 and apo E were 27 kDa 
and 35 kDa, respectively.  
The other issue was to compare the connection between the strength of apolipoprotein and 
the purification procedures. The various purification methods used for the experiment were 
all able to detect apolipoproteins, but PEG/UC gave outstanding results, as evidenced by 
comparing the images in Figure 4, Figure 5, and Figure 6. Bands are more intense in the 
images in Figure 5. 
Lastly, experimental results can be compared to clinical laboratory results. Apo A1 and Apo 
E can be compared to the HDL - cholesterol values in the clinical laboratory results. The link 
between the clinical laboratory results and the experimental work is that a higher clinical 
result is represented by the higher intensity bands in the western blotting results.  
In a word, my research is based on determining the prevalence of apolipoproteins in EVs, if 
this prevalence is dependent on the method used, and how it could be linked to clinical anal-
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